Your session is about to expire
← Back to Search
Procedure
Lung Transplant Techniques for Lung Transplant
N/A
Recruiting
Led By Mauricio Villavicencio, MD, MBA
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 48-72 hours and 90 days
Awards & highlights
No Placebo-Only Group
Summary
This trial is comparing two techniques for performing a bilateral lung transplant: off-pump vs venoarterial ECMO. The goal is to determine which has lower rates of primary graft dysfunction.
Who is the study for?
This trial is for people who need both lungs replaced and can have surgery with or without a heart-lung machine (ECMO), as decided by their surgeon. They must have a certain level of blood pressure in the lungs to qualify. It's not for those needing only one lung, multiple organs, re-transplants, or who had major lung surgeries before.
What is being tested?
The study compares two ways to do lung transplants: 'off-pump' without using ECMO and using venoarterial ECMO during the procedure. The main focus is on which method leads to fewer complications with the new lungs starting to work ('primary graft dysfunction').
What are the potential side effects?
Potential side effects may include issues related to the surgical procedure such as bleeding, infection, or problems with how well the new lungs work. Using ECMO might also lead to blood clots or damage at the site where it's connected.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ during va ecmo run
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during va ecmo run
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Mortality
Lung
Lung
Secondary study objectives
Chest tube output
Incidence of Primary Lung Graft Dysfunction (PGD) grade 3
Incidence of air emboli
+10 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Active Control
Group I: Off-Pump Bilateral Lung TransplantationActive Control1 Intervention
Subjects will receive 'off-pump' technique for lung transplantation as part of standard of care
Group II: Venoarterial Extra Corporeal Membrane Oxygenation (VA ECMO) Bilateral Lung TransplantationActive Control1 Intervention
Subjects will receive VA ECMO technique for lung transplantation as part of standard of care
Find a Location
Who is running the clinical trial?
Mayo ClinicLead Sponsor
3,362 Previous Clinical Trials
3,065,733 Total Patients Enrolled
6 Trials studying Lung Transplant
7,713 Patients Enrolled for Lung Transplant
Mauricio Villavicencio, MD, MBAPrincipal InvestigatorMayo Clinic
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My organ donor died of cardiac failure.I plan to use a machine to help my heart and lungs after surgery.I have had a single lung transplant.I am undergoing a second transplant.I have received a transplant for both of my lungs.I am on or have been on a lung or heart-lung machine before surgery.I have received multiple organ transplants.I have had a procedure to fuse my lung lining.My surgeon thinks I can have surgery without using a heart-lung machine.I have not had major lung surgery, except for VATS or a wedge resection.
Research Study Groups:
This trial has the following groups:- Group 1: Off-Pump Bilateral Lung Transplantation
- Group 2: Venoarterial Extra Corporeal Membrane Oxygenation (VA ECMO) Bilateral Lung Transplantation
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.